A study of metabolic syndrome and cardiovascular disease risk status in highly active antiretroviral therapy-naive patients with human immunodeficiency virus infection

doi:10.3969/j.issn.1006-7795.2020.01.008

Abstract

Abstract: Objective To investigate the clinical characteristics as well of metabolic syndrome(MS) and risk status of cardiovascular disease in highly active antiretroviral therapy(HAART)-naive patients with human immunodeficiency virus(HIV) infection.Methods With 193 HIV infected patients as the study subjects, patients with(case group)and without(control group)MS were identified according to the MS diagnostic criteria, According to the Framingham risk score, patients with high risk of cardiovascular disease were selected as middle and high risk group, and those with low risk were selected as low risk group. Clinical characteristics were analysed by comparing the two groups. Results In our research, the prevalence of MS was 9.33%. The largest component was body mass index (BMI) ≥ 25 kg/m², followed by a decrease in high density lipoprotein cholesterol(HDL-C).Compared with the control group, patients with MS were older, and they had larger body mass index (BMI) (P < 0.05). The cardiovascular risk of MS patients was significantly higher than those without MS.Age, BMI and smoking history were associated with cardiovascular risk in newly diagnosed HIV patients. Patients at high risk of coronary heart disease had higher HIV RNA load, but the difference was not statistically significant.Conclusion Age and BMI were associated with the risk of metabolic syndrome.Cardiovascular risk of MS patients was significantly higher than those without MS.Related risk factors should be evaluated before HAART, and metabolic disorders and cardiovascular diseases should be closely monitored.

Key words: human immunodeficiency virus, highly active antiretroviral therapy-naive, metabolic syndrome, cardiovascular disease risk

CLC Number:

R589

Wang Yanxue, Hu Hongying, Li Xingang, Lu Xingmeng, Gao Guiju, Liang Hongyuan, Xiao Jiang, Yang Di, Wang Fang, Han Xiaotao. A study of metabolic syndrome and cardiovascular disease risk status in highly active antiretroviral therapy-naive patients with human immunodeficiency virus infection[J]. Journal of Capital Medical University, 2020, 41(1): 40-44.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2020.01.008

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2020/V41/I1/40

References

[1] Kibirige D, Ssekitoleko R. Endocrine and metabolic abnormalities among HIV-infected patients:a current review[J]. Int J STD AIDS,2013, 24(8):603-611.
[2] 中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中华糖尿病杂志,2004,12(3):156-161.
[3] 郭海健,念馨,梁友芳,等.基于多中心横断面调查的中国人群代谢综合征的流行情况及危险因素[J].中华疾病控制杂志, 2019,23(7):796-801.
[4] 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防与控制中心.中国艾滋病诊疗指南(2018版)[J].新发传染病电子杂志, 2019,4(2):65-84.
[5] Pearson T A, Blair S N, Daniels S R, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke:2002 update:consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee[J]. Circulation, 2002, 106(3):388-391.
[6] Quiros-Roldan E, Raffetti E, Focà E, et al. Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade:a population-based study from 2000 to 2012[J]. AIDS Care, 2016, 28(12):1551-1558.
[7] Wand H, Calmy A, Carey D L, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection[J]. AIDS, 2007, 21(18):2445-2453.
[8] Nix L M, Tien P C. Metabolic syndrome, diabetes, and cardiovascular risk in HIV[J]. Curr HIV/AIDS Rep, 2014, 11(3):271-278.
[9] Raposo M A, Armiliato G N A, Guimaraães N S, et al. Metabolic disorders and cardiovascular risk in people living with HIV/AIDS without the use of antiretroviral therapy[J]. Rev Soc Bras Med Trop, 2017, 50(5):598-606.
[10] Muhammad F Y, Gezawa I D, Uloko A,et al. Metabolic syndrome among HIV infected patients:a comparative cross sectional study in northwestern Nigeria[J]. Diabetes Metab Syndr, 2017, 11 Suppl 1:S523-S529.
[11] Shen Y, Wang Z, Liu L, et al. Prevalence of hyperglycemia among adults with newly diagnosed HIV/AIDS in China[J]. BMC Infect Dis, 2013,13:79.
[12] Wu P Y, Hung C C, Liu W C, et al. Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy:prevalence and associated factors[J]. J Antimicrob Chemother, 2012, 67(4):1001-1009.
[13] Bonfanti P, De Socio G V, Ricci E, et al. The feature of metabolic syndrome in HIV naive patients is not the same of those treated:results from a prospective study[J]. Biomed Pharmacother, 2012, 66(5):348-353.
[14] Feinstein M J, Hsue P Y, Benjamin L A, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV:a scientific statement from the American Heart Association[J]. Circulation,2019, 140(2):e98-e124.
[15] Guo F, Hsieh E, Lv W, et al. Cardiovascular disease risk among Chinese antiretroviral-naive adults with advanced HIV disease[J]. BMC Infect Dis, 2017, 17(1):287.